DELTICOM
7.4.2016 15:07:25 CEST | Business Wire | Press release
Springtime is tyre-changing time. However, some people who have been driving on old winter tyres might consider wearing them out completely by leaving them for all summer, thus saving themselves the cost of having the tyres changed as well as the possible cost of a new set of summer tyres. By doing so, they sacrifice their own safety and purchasing efficiency.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160407005795/en/
The properties of summer and winter tyres are designed to meet the specific requirements of weather conditions at different times of year. In this way, they ensure optimum efficiency and safety in the prevailing weather conditions. While it may be very tempting to drive straight through to autumn on winter tyres, in warm temperatures summer tyres are a better choice. The general rule of thumb is: from Easter to October. Once the average temperature is mostly above seven degrees Celsius, summer tyres show off all their advantages.
Even Germany’s largest automobile association, ADAC, warns against driving on winter tyres during summer. The reason: due to the soft tread compound used in winter tyres, they are not suited to warm temperatures and offer less grip. When the weather gets warmer, the tread quickly wears off and braking performance is significantly affected. ADAC tests on winter tyres have shown that in summer, stopping distances at approx. 60mph/h may be extended by up to 16 metres. If tyres are also heated further through heavy vehicle loads, winter tyre side walls can suffer damage, and parts of the tread can even come unstuck.
“We recommend changing to summer tyres now, because they are the only tyres that offer the right custom profile and special rubber compound for warmer weather and therefore ensure good grip and shorter breaking distances”, advises Thierry Delesalle from Mytyres.co.uk. “If you’re thinking of leaving your winter tyres on, you won’t do your wallet any favours: in warm weather, winter tyres can increase fuel consumption by up to 15%”, explains Delesalle.
So save now and hit the road properly equipped: just click on Mytyres.co.uk and enjoy a wide range of suitable summer tyres at great prices - quickly, easily and securely. Tyres can be delivered either to the customer’s preferred address, or to one of over 2,000 partner fitting stations across the UK. Many partner workshops also offer customers competitive prices for storing their winter tyres at the workshop until the following winter.
The most important hints on the changing of summer tyres can be also found in the following video: https://www.youtube.com/watch?v=OE5wWgUmi2k&nohtml5
About Mytyres.co.uk
There are over 100 tyre brands and more than 25,000 models of tyres to be found at Mytyres.co.uk - also including the latest best-rated tyres from official comparison tests. The product portfolio not only includes tyres for cars , motorbikes , lorries, commercial vehicles and buses , but also wheel-tyre sets , rims and car replacement parts and accessories . Particularly practical: new tyres can be delivered quickly and free of charge* to any address provided. When purchasing tyres, buyers can also choose from more than 2,000 professional car workshop partners across the UK and have the tyres sent to them directly for professional fitting. Many of our partner workshops offer also additional services, such as tyre storage.
*2 tyres and more
Buy tyres online:
www.mytyres.co.uk , www.reifendirekt.de , www.reifendirekt.at , www.reifendirekt.ch , www.123pneus.ch , www.autobandenmarkt.nl , www.123pneus.fr , www.gommadiretto.it , www.neumaticos-online.es and in many other Delticom online shops.
Tyre tests: www.tyretest.com
Information about the company: www.delti.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160407005795/en/
Contact:
insignis Agency for Kommunikation GmbH (GPRA)
Henning Jahns
Tel.:
+49-511-132214-14
Fax: +49-511-132214-99
delticom@insignis.de
or
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom